Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553787 · ClinicalTrials.gov registry record · Phase 3
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by VIVUS.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,487
- Enrollment target
- 6
- Study locations
NCT00553787 is a Phase 3 study of Obesity and Type 2 Diabetes that has completed, run by VIVUS. The registered enrollment target is 2,487 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (204% higher). The trial reports 6 study locations across 6 states.
The verdict
NCT00553787, a Phase 3 study of Obesity and Type 2 Diabetes, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,487 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
Conditions Studied
Interventions
- DRUG VI-0521
Study Locations (6)
Alabama
- Research Site - Birmingham
Connecticut
- Research Site - Ridgefield
New York
- Research Site - New York
North Carolina
- Research Site - Durham
Ohio
- Research Site - Toledo
Texas
- Research Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,487 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00553787
The ClinicalTrials.gov registry entry for NCT00553787 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,487 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (204% higher). The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which VI-0521 is the first listed.
NCT00553787 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Alabama, Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT00553787 about?
NCT00553787 is a clinical study titled "Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions". The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
What is the current status of trial NCT00553787?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,487 participants. The study started on 2007-11. Estimated completion is 2009-06.
What conditions does trial NCT00553787 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes.
What interventions are being tested in trial NCT00553787?
The interventions under investigation include: VI-0521 (DRUG).
Who is sponsoring clinical trial NCT00553787?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00553787 being conducted?
This trial has 6 study locations across Alabama, Connecticut, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.